CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body’s ability to rebuild and repair its own cells and tissues, today announced that results from the Phase 1 clinical trial with the therapeutic candidate ACE-083, will be presented at the 14th International Congress on Neuromuscular Disease (ICNMD 2016). The meeting will be held in Toronto, Canada from July 5-9, 2016.
|
Clinical Poster Presentation: |
||||
| Title: | ACE-083, A Locally-Acting Muscle Agent, Increases Muscle Volume in Healthy Volunteers (Abstract 266) | |||
| Session: | Poster Session 2 | |||
| Date: | Friday, July 8, 2016 to Saturday, July 9, 2016 | |||
| Time: | 10:30 AM to 12:00 PM EDT on each day | |||
| Location: | Exhibit Hall, Sheraton Hall A – F, Sheraton Centre Toronto Hotel | |||
ACE-083 is designed to selectively increase muscle mass and strength in the muscles in which the drug is administered. Acceleron intends to advance ACE-083 into a Phase 2 clinical trial in patients with facioscapulohumeral muscular dystrophy in the second half of 2016.
The clinical poster will be available on Acceleron's website (www.acceleronpharma.com) under the Science tab.
About Acceleron
Acceleron discovers and develops novel therapies to treat a wide range of rare diseases. Its pioneering research platform leverages the powerful biology behind the body’s ability to rebuild and repair its own cells and tissues. This innovative approach to drug discovery has generated four therapeutic candidates currently in clinical trials. The Company’s lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases, myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.
For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements about Acceleron's strategy, future plans and prospects, including statements regarding the development of ACE-083, the timeline for clinical development and regulatory approval of Acceleron's compounds, the expected timing for the reporting of data from ongoing trials, and the structure of Acceleron's planned or pending clinical trials. The words "anticipate," "appear," "believe," "continue," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks that preclinical testing of Acceleron's compounds and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that data may not be available when Acceleron expects it to be, that Acceleron will be unable to successfully complete the clinical development of Acceleron's compounds, that the development of Acceleron's compounds will take longer or cost more than planned, that Acceleron may be delayed in initiating or completing any clinical trials, and that Acceleron's compounds will not receive regulatory approval or become commercially successful products.
Other risks and uncertainties include those identified under the heading "Risk Factors" included in Acceleron's Annual Report on Form 10-K which was filed with the Securities and Exchange Commission (SEC) on February 25, 2016, and other filings that Acceleron has made and may make with the SEC in the future. The forward-looking statements contained in this press release reflect Acceleron's current views with respect to future events, and Acceleron does not undertake and specifically disclaims any obligation to update any forward-looking statements.